01061 ESSEX BIO-TECH
- 2.590
- +0.010+0.39%
ESSEX BIO-TECH News
Here's Why We Think Essex Bio-Technology Limited's (HKG:1061) CEO Compensation Looks Fair
Key Insights Essex Bio-Technology will host its Annual General Meeting on 28th of May CEO Haizhou Fang's total compensation includes salary of HK$1.70m Total compensation is 79% below industry ave
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Interpretation of ESG Annual Report|Yisheng Biotechnology (01061) Releases 2023 ESG Report Greenhouse Gas Density Decreased by 33.3% YoY
Zhitong Finance App News. Recently, Yisheng Biotechnology (01061) released the “2023 Environmental, Social and Governance Report”, which sets out the Group's strategies and practices in the three areas of environmental protection, social responsibility and operational governance for the year ended December 31, 2023, covering the business operated by the Group. According to reports, Yisheng Biotechnology is mainly engaged in manufacturing, sales, marketing and distribution of pharmaceuticals, and its main operating area is China. According to the ESG report, the board of directors of Yisheng Biotech bears full responsibility for the company's ESG strategy and ESG report, and is responsible for evaluating and determining ESG-related risks and
ESSEX BIO-TECH: ANNUAL REPORT 2023
ESSEX BIO-TECH To Go Ex-Dividend On May 30th, 2024 With 0.045 HKD Dividend Per Share
March 19th - $ESSEX BIO-TECH(01061.HK)$ is trading ex-dividend on May 30th, 2024. Shareholders of record on May 31st, 2024 will receive 0.045 HKD dividend per share on June 17th, 2024. The ex-divi
Essex Bio-Technology's 2023 Profit Jumps 22% on Higher Turnover
Essex Bio-Technology's (HKG:1061) profit increased 22.1% to HK$275.3 million, or HK$0.469 per share, in 2023, from HK$225.4 million, or HK$0.3828 per share, in 2022, according to a Monday filing with
Gelonghui Announcements Selected (Hong Kong Stock) | Reading Group (00772.HK) Announces Annual Results Monthly Paying User Growth of Its Own Platform Products by Over 20%, Officially Entering the Boutique Short Drama Market
[Today's Focus] Reading Text Group (00772.HK) announced its annual results, with monthly paying users of its platform products growing by more than 20%. Reading Group (00772.HK) announced that for the year ended December 31, 2023, the company's revenue reached RMB 7,011.8 million, and the profit attributable to the company's equity holders increased 32.3% year-on-year to RMB 804.9 million. The average monthly paying users of the company's own platform products and self-operated channels increased 10.1% year-on-year from 7.9 million to 8.7 million in the same year. In particular, the company's own platform
Yisheng Biotechnology (01061.HK)'s profit in 2023 increased 22.1% year-on-year to approximately HK$275.3 million
Gelonghui, March 18, 丨 Yisheng Biotechnology (01061.HK) announced that for the year ended December 31, 2023, the Group recorded a consolidated turnover of approximately HK$1,707 billion, an increase of 29.5% over the previous year. Accordingly, the Group's profit increased by 22.1% compared to 2022 to approximately HK$275.3 million, which was particularly hampered by the resulting withholding tax. After considering the full conversion of convertible loans, the basic and diluted earnings per share attributable to the owners of the company were HK$48.27 and HK46.90 cents, respectively. The Group's vision is to become a great company with a sense of social responsibility. In terms of business strategy,
Yisheng Biotechnology (01061) will pay a final dividend of HK$0.045 per share on June 17
Yisheng Biotechnology (01061) announced that the company will pay a final dividend per share on June 17, 2024...
ESSEX BIO-TECH: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Yisheng Biotechnology (01061.HK) held a board meeting on March 18 to discuss and approve annual results
Gelonghui, March 6, 丨 Yisheng Biotechnology (01061.HK) announced that the board of directors will hold a board meeting at 4:00 p.m. on March 18, 2024 (Monday) at room 3206, West Tower, Shun Tak Centre, 168-200 Connaught Road Central, Hong Kong. The agenda includes but is not limited to discussing and approving the annual results of the company and its subsidiaries for the year ended 31 December 2023, and considering payment of a final dividend (if any).
ESSEX BIO-TECH: NOTICE OF BOARD MEETING
Yisheng Biotechnology (01061.HK) cancelled 45,000 shares repurchased on January 30
On January 30, Gelonghui | Yisheng Biotechnology (01061.HK) announced that on January 30, 2024, the company cancelled 45,000 repurchased shares.
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Yisheng Biotechnology (01061.HK) repurchased 1000 shares on January 24
Gelonghui, January 24, 丨 Yisheng Biotechnology (01061.HK) announced that on January 24, 2024, 1,000 shares will be repurchased at HK$2,300 at a repurchase price of HK$2.3 per share.
Yisheng Biotechnology (01061.HK) repurchased 5,000 shares on January 10th
Gelonghui, January 10, 丨 Yisheng Biotechnology (01061.HK) issued an announcement. On January 10, 2024, 5,000 shares were repurchased at HK$11.76 million at a repurchase price of HK$2.31 to HK$2.38 per share.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Pioneer Securities Pharmaceutical's 24-year Strategy: Risks have been fully released, and subsequent industry valuations are expected to rise steadily
The Zhitong Finance App learned that Pioneer Securities released a research report saying that due to more scientific collection rules, after the collection gradually covered a large stock of generic drugs/high-value consumables, the performance was clear, and new performance growth points were formed after innovative products were launched one after another, and the drugs/device-related companies in the hospital will usher in a new growth cycle after their performance stabilizes.
Guotai Junan: The pharmaceutical industry has a low market risk appetite and selects “cost-effective” stocks with steady management
Guotai Junan released a research report saying that the high base effect in COVID-related fields dissipated throughout the year, and the growth rate is expected to gradually return to its own path, but Q1, especially in January-February, was still affected by the base effect of the epidemic.
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
Analysis
Price Target
No Data
